Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tezatabep matraxetan - Affibody

Next Previous
Drug Profile

Tezatabep matraxetan - Affibody

Alternative Names: [111In]ABY-025; [68Ga]ABY-025; ABY-002; ABY-025; ABY0125; Anti-HER2 Affibody

Latest Information Update: 16 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affibody; GE Healthcare
  • Developer Affibody; Biomedical Radiation Sciences; Herlev Hospital; Swedish Cancer Society
  • Class Peptide fragments; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III HER2 positive breast cancer
  • Phase II Solid tumours
  • Preclinical Gastric cancer; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 12 May 2025 Affibody plans a phase II trial for Breast cancer (Diagnosis) in Sweden (IV, Injection) in May 2025 (CTIS2024-512721-89-00)
  • 20 Feb 2025 Vanderbilt-Ingram Cancer Center plans a phase 0 trial for HER 2 positive breast cancer (Diagnosis) in USA (IV, Infusion) in February 2025 (NCT06828588)
  • 06 Dec 2022 Preclinical trials in Gastric cancer (Diagnosis) in Sweden (IV), prior to December 2022 (Affibody Pipeline, December 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top